CHU Caen Normandie
Caen, 14000, France
NCT Number: NCT05419258
The new Uplug° technology, interface between the end of the hemodialysis catheter and the dialysis circuit, makes it possible to limit direct access to the hemodialysis catheter during connections and disconnections.
Aim:
The investigators propose a feasibility study, in order to study the new Uplug° technology in real conditions of use.
Material and methods:
This study aim to include 15 hemodialysis patients in a center on a tunneled permanent central venous hemodialysis catheter. The Uplug° technology will be placed at the end of each patient's hemodialysis catheter for a period of one month.
Hypothesis tested:
The main endpoint is the proportion of hemodialysis sessions performed successfully with this technology, respecting the usual dialysis prescription.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Caen, 14000, France
The incidence and prevalence of chronic insufficiency have been growing for several years. Increasingly older patients are treated with chronic hemodialysis. The vascular access of choice remains the arteriovenous fistula and the proportion of hemodialysis patients on the permanent central venous hemodialysis catheter varies from 20 to 35% in dialysis centres. The new Uplug° technology, interface between the end of the hemodialysis catheter and the dialysis circuit, makes it possible to limit direct access to the hemodialysis catheter during connections and disconnections.
Aim:
The investigators propose a feasibility study, in order to study the new Uplug° technology in real conditions of use.
Material and methods:
This study aim to include 15 hemodialysis patients in a center on a tunneled permanent central venous hemodialysis catheter. The inclusion period is three months. The follow-up time for each participant is 6 weeks. Patients with a tunneled permanent central venous hemodialysis catheter and performing dialysis sessions with a flow rate ≥ 300 ml/min may be included. The Uplug° technology will be placed at the end of each patient's hemodialysis catheter for a period of one month.
Hypothesis tested:
The main endpoint is the proportion of hemodialysis sessions performed successfully with this technology, respecting the usual dialysis prescription.
The secondary objectives are the infectious risk, the defects of the experimental device and the hemodialysis catheter or their implementation, the satisfaction of the nursing staff and the patient, the reduction in the number of manipulations and the effective time of these manipulations.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
use of the device UPLUG during 1 month
Time frame: one month
Study the feasibility of performing dialysis with the UPlug Technology in patients with a permanent tunneled central venous hemodialysis catheter with the objective of a success rate ≥ 80%.
Time frame: one month
adverse events reported from consent to end of study
Time frame: one month
device deficiencies reported from consent to end of study
Time frame: one month
satisfaction evaluated by questionnaire before and after the inclusions
Time frame: one month
satisfaction evaluated by questionnaire before and after the use of experimental device
Time frame: one month
performance measured by rate of successful sessions
University Hospital, Caen
Other
Acronym: UPLUG-SAFE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00891813
Calcium Metabolism Disorders, Chronic Disease
Callao, Peru
View Trial DetailsNCT06660277
Chronic Disease, Chronic Kidney Disease Requiring Chronic Dialysis
London, Ontario, Canada
View Trial DetailsNCT06648876
Chronic Disease, Diabetes
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06759376
Chronic Disease, Chronic Kidney Disease
Eskişehir, Turkiye, Turkey (Türkiye)
View Trial Details